Proteasome inhibition by bortezomib increases IL-8 expression in androgen-independent prostate cancer cells: The role of IKKα

Journal of Immunology

Volumn 191, Issue 5, 2013, Pages 2837-2846

  Manna, Subrata ^a   Singha, Bipradeb ^a   Phyo, Sai Aung ^a   Gatla, Himavanth Reddy ^a   Chang, Tzu Pei ^a   Sanacora, Shannon ^a   Ramaswami, Sitharam ^a,b   Vancurova, Ivana ^a  

^a ST JOHN'S UNIVERSITY   (United States)

^b Columbia University Medical School ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; I KAPPA B KINASE ALPHA; INTERLEUKIN 8; MESSENGER RNA; PROTEASOME; TRANSCRIPTION FACTOR RELA;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG DNA BINDING; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; IN VITRO STUDY; INTERLEUKIN 8 GENE; NF KAPPAB GENE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN FUNCTION; UPREGULATION;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BORONIC ACIDS; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; I-KAPPA B KINASE; INTERLEUKIN-8; MALE; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84883360510     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300895     Document Type: Article

References (71)

1. Kunkel, S. L., R. M. Strieter, S. W. Chensue, M. Basha, T. Standiford, J. Ham, and D. G. Remick. 1990. Tumor necrosis factor-alpha, interleukin-8 and chemotactic cytokines. Prog. Clin. Biol. Res. 349: 433-444.
2. Waugh, D. J., and C. Wilson. 2008. The interleukin-8 pathway in cancer. Clin. Cancer Res. 14: 6735-6741.
3. Inoue, K., J. W. Slaton, B. Y. Eve, S. J. Kim, P. Perrotte, M. D. Balbay, S. Yano, M. Bar-Eli, R. Radinsky, C. A. Pettaway, and C. P. Dinney. 2000. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin. Cancer Res. 6: 2104-2119.
4. Araki, S., Y. Omori, D. Lyn, R. K. Singh, D. M. Meinbach, Y. Sandman, V. B. Lokeshwar, and B. L. Lokeshwar. 2007. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res. 67: 6854-6862.
5. Aggarwal, B. B. 2004. Nuclear factor-kappaB: the enemy within. Cancer Cell 6: 203-208.
6. Bassères, D. S., and A. S. Baldwin. 2006. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25: 6817-6830.
7. DiDonato, J. A., F. Mercurio, and M. Karin. 2012. NF-κB and the link between inflammation and cancer. Immunol. Rev. 246: 379-400.
8. Hayden, M. S., and S. Ghosh. 2012. NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 26: 203-234.
9. Palayoor, S. T., M. Y. Youmell, S. K. Calderwood, C. N. Coleman, and B. D. Price. 1999. Constitutive activation of IkappaB kinase alpha and NFkappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene 18: 7389-7394.
10. Chen, C. D., and C. L. Sawyers. 2002. NF-k B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol. Cell. Biol. 22: 2862-2870.
11. Gasparian, A. V., Y. J. Yao, D. Kowalczyk, L. A. Lyakh, A. Karseladze, T. J. Slaga, and I. V. Budunova. 2002. The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J. Cell Sci. 115: 141-151.
12. Jin, R. J., Y. Lho, L. Connelly, Y. Wang, X. Yu, L. Saint Jean, T. C. Case, K. Ellwood-Yen, C. L. Sawyers, N. A. Bhowmick, et al. 2008. The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgenindependent growth. Cancer Res. 68: 6762-6769.
13. Jain, G., M. V. Cronauer, M. Schrader, P. Möller, and R. B. Marienfeld. 2012. NF-κB signaling in prostate cancer: a promising therapeutic target? World J. Urol. 30: 303-310.
14. Singh, R. K., and B. L. Lokeshwar. 2011. The IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth. Cancer Res. 71: 3268-3277.
15. Singh, R. K., A. Sudhakar, and B. L. Lokeshwar. 2010. Role of chemokines and chemokine receptors in prostate cancer development and progression. J Cancer Sci. Ther. 2: 89-94.
16. Hayden, M. S., and S. Ghosh. 2008. Shared principles in NF-kappaB signaling. Cell 132: 344-362.
17. Liu, F., Y. Xia, A. S. Parker, and I. M. Verma. 2012. IKK biology. Immunol. Rev. 246: 239-253.
18. Teicher, B. A., G. Ara, R. Herbst, V. J. Palombella, and J. Adams. 1999. The proteasome inhibitor PS-341 in cancer therapy. Clin. Cancer Res. 5: 2638-2645.
19. Cusack, J. C., Jr., R. Liu, M. Houston, K. Abendroth, P. J. Elliott, J. Adams, and A. S. Baldwin, Jr. 2001. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 61: 3535-3540.
20. Hideshima, T., P. Richardson, D. Chauhan, V. J. Palombella, P. J. Elliott, J. Adams, and K. C. Anderson. 2001. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61: 3071-3076.
21. Hideshima, T., C. Mitsiades, M. Akiyama, T. Hayashi, D. Chauhan, P. Richardson, R. Schlossman, K. Podar, N. C. Munshi, N. Mitsiades, and K. C. Anderson. 2003. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101: 1530-1534.
22. Richardson, P. G., C. Mitsiades, T. Hideshima, and K. C. Anderson. 2005. Proteasome inhibition in the treatment of cancer. Cell Cycle 4: 290-296.
23. Williams, S., C. Pettaway, R. Song, C. Papandreou, C. Logothetis, and D. J. McConkey. 2003. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol. Cancer Ther. 2: 835-843.
24. Papandreou, C. N., D. D. Daliani, D. Nix, H. Yang, T. Madden, X. Wang, C. S. Pien, R. E. Millikan, S. M. Tu, L. Pagliaro, et al. 2004. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J. Clin. Oncol. 22: 2108-2121.
25. Papandreou, C. N., and C. J. Logothetis. 2004. Bortezomib as a potential treatment for prostate cancer. Cancer Res. 64: 5036-5043.
26. McConkey, D. J., and K. Zhu. 2008. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist. Updat. 11: 164-179.
27. Zhu, K., K. Dunner, Jr., and D. J. McConkey. 2010. Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells. Oncogene 29: 451-462.
28. Voutsadakis, I. A., and C. N. Papandreou. 2012. The ubiquitin-proteasome system in prostate cancer and its transition to castration resistance. Urol. Oncol. 30: 752-761.
29. Wright, J. J. 2010. Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin. Cancer Res. 16: 4094-4104.
30. Kraft, A. S., E. Garrett-Mayer, A. E. Wahlquist, A. Golshayan, C. S. Chen, W. Butler, J. Bearden, and M. Lilly. 2011. Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade. Cancer Biol. Ther. 12: 119-124.
31. Vu, H. Y., A. Juvekar, C. Ghosh, S. Ramaswami, D. H. Le, and I. Vancurova. 2008. Proteasome inhibitors induce apoptosis of prostate cancer cells by inducing nuclear translocation of IkappaBalpha. Arch. Biochem. Biophys. 475: 156-163.
32. Ghosh, C. C., S. Ramaswami, A. Juvekar, H. Y. Vu, L. Galdieri, D. Davidson, and I. Vancurova. 2010. Gene-specific repression of proinflammatory cytokines in stimulated human macrophages by nuclear IkBa. J. Immunol. 185: 3685-3693.
33. Juvekar, A., S. Manna, S. Ramaswami, T. P. Chang, H. Y. Vu, C. C. Ghosh, M. Y. Celiker, and I. Vancurova. 2011. Bortezomib induces nuclear translocation of IkBa resulting in gene-specific suppression of NF-κB-dependent transcription and induction of apoptosis in CTCL. Mol. Cancer Res. 9: 183-194.
34. Ramaswami, S., S. Manna, A. Juvekar, S. Kennedy, A. Vancura, and I. Vancurova. 2012. Chromatin immunoprecipitation analysis of NFκB transcriptional regulation by nuclear IκBα in human macrophages. Methods Mol. Biol. 809: 121-134.
35. Ross, J. S., B. V. Kallakury, C. E. Sheehan, H. A. Fisher, R. P. Kaufman, Jr., P. Kaur, K. Gray, and B. Stringer. 2004. Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence. Clin. Cancer Res. 10: 2466-2472.
36. Shukla, S., G. T. MacLennan, P. Fu, J. Patel, S. R. Marengo, M. I. Resnick, and S. Gupta. 2004. Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia 6: 390-400.
37. Sweeney, C., L. Li, R. Shanmugam, P. Bhat-Nakshatri, V. Jayaprakasan, L. A. Baldridge, T. Gardner, M. Smith, H. Nakshatri, and L. Cheng. 2004. Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin. Cancer Res. 10: 5501-5507.
38. Fradet, V., L. Lessard, L. R. Bégin, P. Karakiewicz, A. M. Masson, and F. Saad. 2004. Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clin. Cancer Res. 10: 8460-8464.
39. Levêque, D., M. C. Carvalho, and F. Maloisel. 2007. Review. Clinical pharmacokinetics of bortezomib. In Vivo 21: 273-278.
40. Kunsch, C., and C. A. Rosen. 1993. NF-kappa B subunit-specific regulation of the interleukin-8 promoter. Mol. Cell. Biol. 13: 6137-6146.
41. Stein, B., and A. S. Baldwin, Jr. 1993. Distinct mechanisms for regulation of the interleukin-8 gene involve synergism and cooperativity between C/EBP and NFkappa B. Mol. Cell. Biol. 13: 7191-7198.
42. Ma, J., Z. Ren, Y. Ma, L. Xu, Y. Zhao, C. Zheng, Y. Fang, T. Xue, B. Sun, and W. Xiao. 2009. Targeted knockdown of EGR-1 inhibits IL-8 production and IL-8-mediated invasion of prostate cancer cells through suppressing EGR-1/NFkappaB synergy. J. Biol. Chem. 284: 34600-34606.
43. Yemelyanov, A., A. Gasparian, P. Lindholm, L. Dang, J. W. Pierce, F. Kisseljov, A. Karseladze, and I. Budunova. 2006. Effects of IKK inhibitor PS1145 on NFkappaB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells. Oncogene 25: 387-398.
44. Gasparian, A. V., O. A. Guryanova, D. V. Chebotaev, A. A. Shishkin, A. Y. Yemelyanov, and I. V. Budunova. 2009. Targeting transcription factor NFkappaB: comparative analysis of proteasome and IKK inhibitors. Cell Cycle 8: 1559-1566.
45. Péant, B., J. S. Diallo, F. Dufour, C. Le Page, N. Delvoye, F. Saad, and A. M. Mes-Masson. 2009. Over-expression of IkappaB-kinase-epsilon (IKKepsilon/IKKi) induces secretion of inflammatory cytokines in prostate cancer cell lines. Prostate 69: 706-718.
46. Péant, B., V. Forest, V. Trudeau, M. Latour, A. M. Mes-Masson, and F. Saad. 2011. IκB-Kinase-ε (IKKε/IKKi/IκBKε) expression and localization in prostate cancer tissues. Prostate 71: 1131-1138.
47. Broemer, M., D. Krappmann, and C. Scheidereit. 2004. Requirement of Hsp90 activity for IkappaB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-kappaB activation. Oncogene 23: 5378-5386.
48. Lee, J., M. H. Rhee, E. Kim, and J. Y. Cho. 2012. BAY 11-7082 is a broadspectrum inhibitor with anti-inflammatory activity against multiple targets. Mediators Inflamm. 2012: 416036.
49. Bain, J., L. Plater, M. Elliott, N. Shpiro, C. J. Hastie, H. McLauchlan, I. Klevernic, J. S. Arthur, D. R. Alessi, and P. Cohen. 2007. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408: 297-315.
50. Jiang, X., N. Takahashi, N. Matsui, T. Tetsuka, and T. Okamoto. 2003. The NF-κ B activation in lymphotoxin beta receptor signaling depends on the phosphorylation of p65 at serine 536. J. Biol. Chem. 278: 919-926.
51. Hoberg, J. E., A. E. Popko, C. S. Ramsey, and M. W. Mayo. 2006. IkappaB kinase alpha-mediated derepression of SMRT potentiates acetylation of RelA/p65 by p300. Mol. Cell. Biol. 26: 457-471.
52. Saccani, S., I. Marazzi, A. A. Beg, and G. Natoli. 2004. Degradation of promoter-bound p65/RelA is essential for the prompt termination of the nuclear factor kappaB response. J. Exp. Med. 200: 107-113.
53. Lawrence, T., M. Bebien, G. Y. Liu, V. Nizet, and M. Karin. 2005. IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature 434: 1138-1143.
54. Cullen, S. J., S. Ponnappan, and U. Ponnappan. 2010. Proteasome inhibition upregulates inflammatory gene transcription induced by an atypical pathway of NF-kappaB activation. Biochem. Pharmacol. 79: 706-714.
55. Demarchi, F., C. Bertoli, P. A. Greer, and C. Schneider. 2005. Ceramide triggers an NF-kappaB-dependent survival pathway through calpain. Cell Death Differ. 12: 512-522.
56. Li, C., S. Chen, P. Yue, X. Deng, S. Lonial, F. R. Khuri, and S. Y. Sun. 2010. Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB (alpha) degradation. J. Biol. Chem. 285: 16096-16104.
57. Plaksin, D., P. A. Baeuerle, and L. Eisenbach. 1993. KBF1 (p50 NF-κ B homodimer) acts as a repressor of H-2Kb gene expression in metastatic tumor cells. J. Exp. Med. 177: 1651-1662.
58. Bohuslav, J., V. V. Kravchenko, G. C. Parry, J. H. Erlich, S. Gerondakis, N. Mackman, and R. J. Ulevitch. 1998. Regulation of an essential innate immune response by the p50 subunit of NF-kappaB. J. Clin. Invest. 102: 1645-1652.
59. Levine, L., J. A. Lucci, III, B. Pazdrak, J. Z. Cheng, Y. S. Guo, C. M. Townsend, Jr., and M. R. Hellmich. 2003. Bombesin stimulates nuclear factor κ B activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res. 63: 3495-3502.
60. Patrikidou, A. P., J. Vlachostergios, I. A. Voutsadakis, E. Hatzidaki, R. M. Valeri, C. Destouni, E. Apostolou, and C. N. Papandreou. 2012. Neuropeptide-inducible upregulation of proteasome activity precedes nuclear factor kappa B activation in androgen-independent prostate cancer cells. Cancer Cell Int. 12: 31.
61. Dolcet, X., D. Llobet, M. Encinas, J. Pallares, A. Cabero, J. A. Schoenenberger, J. X. Comella, and X. Matias-Guiu. 2006. Proteasome inhibitors induce death but activate NF-kappaB on endometrial carcinoma cell lines and primary culture explants. J. Biol. Chem. 281: 22118-22130.
62. Hideshima, T., H. Ikeda, D. Chauhan, Y. Okawa, N. Raje, K. Podar, C. Mitsiades, N. C. Munshi, P. G. Richardson, R. D. Carrasco, and K. C. Anderson. 2009. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 114: 1046-1052.
63. Németh, Z. H., H. R. Wong, K. Odoms, E. A. Deitch, C. Szabó , E. S. Vizi, and G. Haskó. 2004. Proteasome inhibitors induce inhibitory kappa B (I kappa B) kinase activation, I kappa B alpha degradation, and nuclear factor kappa B activation in HT-29 cells. Mol. Pharmacol. 65: 342-349.
64. Luo, J. L., W. Tan, J. M. Ricono, O. Korchynskyi, M. Zhang, S. L. Gonias, D. A. Cheresh, and M. Karin. 2007. Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature 446: 690-694.
65. Jain, G., C. Voogdt, A. Tobias, K. D. Spindler, P. Möller, M. V. Cronauer, and R. B. Marienfeld. 2012. IκB kinases modulate the activity of the androgen receptor in prostate carcinoma cell lines. Neoplasia 14: 178-189.
66. Häcker, H., and M. Karin. 2006. Regulation and function of IKK and IKKrelated kinases. Sci. STKE 2006: re13.
67. Gloire, G., E. Dejardin, and J. Piette. 2006. Extending the nuclear roles of IkappaB kinase subunits. Biochem. Pharmacol. 72: 1081-1089.
68. Lee, D. F., and M. C. Hung. 2008. Advances in targeting IKK and IKK-related kinases for cancer therapy. Clin. Cancer Res. 14: 5656-5662.
69. Espinosa, L., A. Bigas, and M. C. Mulero. 2011. Alternative nuclear functions for NF-κB family members. Am J Cancer Res. 1: 446-459.
70. Huang, W. C., and M. C. Hung. 2013. Beyond NF-κB activation: nuclear functions of IkB kinase a. J. Biomed. Sci. 20: 3. doi: 10.1186/1423-0127-20-3.
71. Gloire, G., J. Horion, N. El Mjiyad, F. Bex, A. Chariot, E. Dejardin, and J. Piette. 2007. Promoter-dependent effect of IKKalpha on NF-kappaB/p65 DNA binding. J. Biol. Chem. 282: 21308-21318.